A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
Clinical trial NCT05791864 · RECRUITING
Trial details
- NCT number
- NCT05791864
- Sponsor
- Tern Therapeutics, LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-17
- Primary completion
- 2026-07-30
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.